SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Shares Bought by Opus Capital Group LLC

Opus Capital Group LLC lifted its holdings in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 291.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 135,000 shares of the company’s stock after purchasing an additional 100,500 shares during the quarter. Opus Capital Group LLC owned about 0.42% of SELLAS Life Sciences Group worth $143,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wells Fargo & Company MN raised its position in SELLAS Life Sciences Group by 44.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,140 shares of the company’s stock valued at $38,000 after purchasing an additional 5,004 shares in the last quarter. Virtu Financial LLC acquired a new stake in SELLAS Life Sciences Group in the fourth quarter valued at approximately $43,000. Northern Trust Corp raised its holdings in SELLAS Life Sciences Group by 31.1% in the second quarter. Northern Trust Corp now owns 39,360 shares of the company’s stock valued at $62,000 after acquiring an additional 9,342 shares in the last quarter. Renaissance Technologies LLC purchased a new position in SELLAS Life Sciences Group in the second quarter worth approximately $75,000. Finally, Two Sigma Investments LP grew its holdings in SELLAS Life Sciences Group by 149.8% during the 3rd quarter. Two Sigma Investments LP now owns 53,685 shares of the company’s stock worth $108,000 after acquiring an additional 32,191 shares in the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Up 3.7 %

SELLAS Life Sciences Group stock traded up $0.05 during midday trading on Wednesday, reaching $1.41. The company’s stock had a trading volume of 560,811 shares, compared to its average volume of 1,456,324. The company has a market cap of $79.34 million, a P/E ratio of -1.03 and a beta of 2.35. The business has a 50-day simple moving average of $1.08 and a 200-day simple moving average of $0.99. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $1.91.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.